Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry

Summary

Venous thromboembolism (VTE) occurs infrequently during pregnancy, and issues concerning its natural history, prevention and therapy remain unresolved. RIETE is an ongoing registry of consecutive patients with objectively confirmed, symptomatic acute VTE. In this analysis, we compared the clinical characteristics and outcome for all enrolled pregnant and postpartum women with acuteVTE, and all non-pregnant women in the same age range. Up to May 2005, 11,630 patients were enrolled in RIETE, of whom 848 (7.3%) were women aged < 47 years. Of them, 72 (8.5%) were pregnant, 64 (7.5%) postpartum. Pregnant women presented less often with symptomatic pulmonary embolism (11%) than non-pregnant women (39%). VTE developed during the first trimester in 29 (40%) pregnant patients; in the second in 13; in the third in 30. Thrombophilia tests were m Venous thromboembolism (VTE) occurs infrequently during pregnancy, and issues concerning its natural history, prevention and therapy remain unresolved. RIETE is an ongoing registry of consecutive patients with objectively confirmed, symptomatic acute VTE. In this analysis, we compared the clinical characteristics and outcome for all enrolled pregnant and postpartum women with acuteVTE, and all non-pregnant women in the same age range. Up to May 2005, 11,630 patients were enrolled in RIETE, of whom 848 (7.3%) were women aged < 47 years. Of them, 72 (8.5%) were pregnant, 64 (7.5%) postpartum. Pregnant women presented less often with symptomatic pulmonary embolism (11%) than non-pregnant women (39%). VTE developed during the first trimester in 29 (40%) pregnant patients; in the second in 13; in the third in 30. Thrombophilia tests were m

Keywords

Venous thromboembolism - prophylaxis - pregnancy

^* A full list of RIETE investigators is given in the Appendix.

• References

• 1 Chang J, Elam-Evans LD, Berg CJ. et al. Pregnancy- related mortality surveillance-United States, 1991–1999. MMWR Surveill Summ 2003; 52: 1-8.
• 2 Monreal M, Suárez C, González Fajardo JA. et al. and the RIETE investigators. Management of patients with acute venous thromboembolism: Findings from the RIETE Registry. J Pathophysiol Haemost Thromb 2003/2004 33: 330-334.
• 3 Monreal M, Kakkar AK, Caprini JA. et al. and the RIETE Investigators. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE Registry. J Thromb Haemost 2004; 2: 1-7.
• 4 Trujillo-Santos J, Perea-Milla E, Jiménez-Puente A. et al. and the RIETE Investigators. Bed rest or ambulation in the initial treatment of patients with acute deep vein trombosis or pulmonary embolism. Findings from the RIETE Registry. Chest 2005; 127: 1631-1636.
• 5 Nieto JA, Díaz de Tuesta A, Marchena PJ. et al. and the RIETE investigators. Clinical outcome of patients with venous thromboembolism and recent major bleeding: Findings from a Prospective Registry (RIETE). J Thromb Haemost 2005; 3: 703-709.
• 6 Barba R, Marco J, Martín-Alvarez H. et al. and the RIETE investigators. The influence of extreme body weight on clinical outcome of patients with venous thrombo-embolism: Findings from a prospective Registry (RIETE). J Thromb Haemost 2005; 3: 856-862.
• 7 Bates SM, Greer IA, Hirsh J. et al. Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 627S-644S.
• 8 Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: A meta-analysis of the period of risk and the leg presentation. Obstet Gynecol Survey 1999; 54: 265-271.
• 9 Sanson BJ, Lensing AW, Prins MH. et al. Safety of low-molecular-weight heparin in pregnancy : A systematic review. Thromb Haemost 1999; 81: 668-672.
• 10 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thrombo-prophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005; 106: 401-407.
• 11 Rowan JA, McLintock C, Taylor RS. et al. Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring. Aust NZ J Obstet Gynaecol 2003; 43: 123-128.
• 12 Smith MP, Norris LA, Steer PJ. et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol 2004; 190: 495-501.
• 13 Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191: 1024-1029.
• 14 Rodie VA, Thomson AJ, Stewart FM. et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG 2002; 109: 1020-1024.
• 15 Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG 2003; 110: 139-144.
• 16 Kupferminc MJ, Eldor A, Steinman N. et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
• 17 Martinelli I, Taioli E, Cetin I. et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-1018.
• 18 Infante-Rivard C, Rivard GE, Yotov Wvet al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002; 347: 19-25.
• 19 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
• 20 Roque H, Paidas MJ, Funai EF. et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004; 91: 290-295.
• 21 Gibson CS, MacLennan AH, Janssen NG. et al. Associations between fetal inherited thrombophilia and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 947.e1-e10.